Nabla Bio and Takeda Forge Landmark $1 Billion AI Partnership to Revolutionize Protein Therapeutics

A New Era in Biologics Discovery: Nabla Bio and Takeda Forge Landmark $1 Billion AI Partnership

In a move that underscores the transformative power of artificial intelligence in pharmaceutical research, Nabla Bio and Takeda have announced a significant expansion of their collaboration. This multi-year partnership, potentially valued at over $1 billion, is set to accelerate the discovery and development of novel protein therapeutics by leveraging Nabla Bio's cutting-edge AI platform. This second major deal between the two entities builds upon the foundational success of their initial engagement, signaling a shared conviction in the potential of AI to unlock new therapeutic frontiers at an unprecedented scale and speed.

The Power of the Joint Atomic Model (JAM)

At the heart of this collaboration lies Nabla Bio's proprietary biomolecular design platform, the Joint Atomic Model (JAM). This sophisticated AI system is engineered for the *de novo* design of protein therapeutics, meaning it can conceptualize and generate entirely new molecules from scratch. The platform is particularly adept at designing antibodies, a crucial class of biologics, and will be deployed across Takeda's early-stage development programs. The scope of the collaboration includes the parallel design of antibodies for multiple targets, the creation of multispecific antibodies (which can target several pathways simultaneously), and the development of therapeutics for challenging and previously intractable targets. This capability is crucial for addressing complex diseases where existing treatment options are limited.

Nabla Bio reports that JAM has achieved remarkable success rates, demonstrating double-digit efficacy in *de novo* design across a diverse range of targets. Notably, it has successfully generated antibodies with picomolar binding affinities – a measure of high potency – for difficult target classes such as G protein-coupled receptors (GPCRs), even in a "true zero-shot" setting, which implies the AI can design effective binders without prior specific training data for that particular target. This ability to design potent binders for challenging targets is a significant advancement in the field.

Integrated AI and Wet-Lab Capabilities

A key differentiator for Nabla Bio is its integrated approach, which combines generative AI with human-relevant *in vitro* and *in vivo* testing. This tight integration ensures that AI-generated designs are not merely theoretical but are rigorously validated through laboratory experiments. The JAM platform, coupled with direct-to-function testing, has already delivered functional antibodies, including GPCR agonists and complex biologics like multispecifics and receptor decoys. Furthermore, therapeutics designed by Nabla's AI have demonstrated exceptional preclinical properties. These include robust function, favorable pharmacokinetics/pharmacodynamics (PK/PD) profiles, and crucially, low immunogenicity in non-human primate studies. These preclinical attributes are vital indicators of a drug's potential for safety and efficacy in human trials.

Strategic Alignment and Financial Commitment

Under the terms of the agreement, Nabla Bio will receive substantial upfront and research cost payments in the "double-digit millions." More significantly, the company is eligible to receive success-based payments that could exceed $1 billion in total. This considerable financial commitment from Takeda highlights the strategic importance of AI-driven drug discovery and Nabla Bio's pivotal role in this domain. The deal comes at a time when Takeda is strategically refocusing its research and development efforts. Following a decision to discontinue its cell therapy research, Takeda is emphasizing more scalable therapeutic modalities, with AI-driven biologics development being a key pillar of this new strategy.

"Since 2022, we’ve collaborated with Takeda to push the boundaries of next-generation biologics discovery," stated Surge Biswas, Ph.D., Chief Executive Officer and Co-founder of Nabla Bio. "This second collaboration builds on the success of our first program and reflects our shared conviction that *de novo* design and AI-driven optimization, powered by foundation models like JAM, can unlock entirely new therapeutic spaces and accelerate the development of new medicines at a scale and speed not seen before."

Echoing this sentiment, Chris Arendt, Ph.D., Chief Scientific Officer and Head of Research at Takeda, commented, "At Takeda, we are accelerating drug development by leveraging the latest advances in AI. Building upon the success of our first engagement with Nabla Bio, this collaboration applies their cutting-edge AI and wet lab to help us design and optimize protein therapeutics for applications across our therapeutic areas."

Broader Industry Trends and Future Implications

The expanded partnership between Takeda and Nabla Bio is emblematic of a broader trend sweeping the pharmaceutical industry. Companies are increasingly turning to AI to overcome the traditional challenges of drug discovery, which are often characterized by lengthy timelines, high costs, and significant attrition rates. The ability of AI platforms like JAM to rapidly design, optimize, and predict the behavior of novel molecules offers a compelling solution to these challenges. Nabla Bio